Welcome to our dedicated page for Baxter Intl SEC filings (Ticker: BAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Baxter International Inc. (NYSE: BAX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered summaries to help interpret complex documents. Baxter is a global medtech company with common stock and certain global notes registered under Section 12(b) of the Exchange Act, and its filings offer insight into capital structure, financing activities, governance and key business developments.
Investors reviewing Baxter’s filings will find Form 8-K reports covering topics such as new senior note offerings due 2029, 2030 and 2035, amendments to credit agreements, tender offers for existing senior unsecured notes due 2026 and 2027, and repayment of a term loan facility. Other 8-Ks detail changes in executive leadership, earnings press releases furnished under Item 2.02, and updates to leverage covenants. These documents outline how Baxter manages its debt profile, liquidity and capital allocation, including refinancing transactions and tender offer results.
Baxter’s filings also confirm its status as a Delaware corporation and list its securities registered on the New York Stock Exchange, including common stock under the symbol BAX and 1.3% global notes due 2029. Disclosures about note terms, ranking, optional redemption provisions, change-of-control repurchase rights and covenants are contained in indentures and supplemental indentures referenced in the exhibits to Form 8-K.
On Stock Titan, AI-generated highlights help users quickly identify key points in Baxter’s 10-K and 10-Q reports (when available), such as segment information, risk factors and liquidity discussions, while Form 4 insider transaction filings can be used to monitor trading by directors and officers. Real-time updates from EDGAR ensure that new Baxter filings appear promptly, and AI summaries provide plain-language explanations of technical sections, helping users understand what each filing may mean for Baxter’s financial obligations, governance and strategic actions.
Dodge & Cox filed Amendment No. 4 to a Schedule 13G reporting a significant passive stake in Baxter International (BAX). The firm beneficially owns 57,396,370 shares, representing 11.2% of Baxter’s common stock. It has sole voting power over 54,118,570 shares and sole dispositive power over 57,396,370 shares.
Dodge & Cox is identified as an investment adviser and certifies the shares were acquired and are held in the ordinary course of business and not to change or influence control. Its clients have rights to receive dividends and sale proceeds. The Dodge & Cox Stock Fund holds 38,623,700 shares, or 7.5% of the class. The reported event date is 09/30/2025.
Baxter International Inc. announced a leadership change: Alok Sonig has resigned as Executive Vice President and Group President, Pharmaceuticals. His resignation is effective December 1, 2025, and he is departing to join a company in the healthcare industry.
The update was disclosed in a current report and pertains only to this executive transition. Baxter’s common stock trades on the NYSE under BAX, and its 1.3% Global Notes due 2029 trade as BAX 29 on the NYSE.
Baxter International (BAX) reported Q3 2025 results with net sales of $2,835 million, operating income of $172 million, and a loss from continuing operations of $51 million after $172 million of income tax expense. Net loss was $46 million. Gross margin was $950 million versus $1,033 million a year ago, while interest expense fell to $58 million from $87 million.
The company closed the sale of its Kidney Care business on January 31, 2025, receiving approximately $3.71 billion in pre-tax cash at closing and recognizing a year-to-date pre-tax gain of $115 million. Final working capital adjustments reduced the Q3 gain by $55 million. Year-to-date, Baxter repaid $3,505 million of debt, including retiring a $1.83 billion bridge facility, and cut long-term debt to $8,747 million from $10,374 million, with only $4 million of short-term debt outstanding. The amended $2.20 billion multicurrency revolver had no borrowings at quarter-end.
Baxter recorded Hurricane Helene-related charges of $8 million in Q3 and $123 million year-to-date. The company initiated Class I recalls for the Novum IQ Large Volume Pump and temporarily stopped distribution in the U.S. and Canada, recording a remediation reserve that was not material.
Baxter International Inc. filed an 8-K announcing it furnished an earnings press release for the period ended September 30, 2025. The press release is attached as Exhibit 99.1. The company states the information in Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed filed under the Exchange Act. Exhibits also include the Cover Page Interactive Data File as Exhibit 104.
Baxter International (BAX) announced a leadership change. Heather Knight will resign as Executive Vice President, Chief Operating Officer, and interim group president of Medical Products and Therapies (MPT) effective October 29, 2025, to join a company in the healthcare industry.
On the transition date, President and CEO Andrew Hider will also serve as interim group president of MPT, and Baxter will eliminate the COO role. This consolidates operational oversight under the CEO while the company manages the MPT leadership transition.
BlackRock Portfolio Management LLC filed a Schedule 13G/A reporting beneficial ownership of 39,204,985 shares (7.6%) of Baxter International (BAX) common stock as of 09/30/2025.
The filer reports 38,736,192 shares with sole voting power and 39,204,985 shares with sole dispositive power. The certification states the securities were acquired and are held in the ordinary course and not to change or influence control.
Alok Sonig, EVP & Group President, Pharma at Baxter International (BAX), reported a transaction on 09/02/2025. He relinquished 3,191 shares of Baxter common stock at a price of $24.17 per share to cover tax withholding tied to the delivery of vested restricted stock units granted on 09/01/2022. After the transaction, the reporting person beneficially owns 128,219 shares, which the filing notes includes automatic dividend reinvestment. The sale was reported on a Form 4 signed by an attorney-in-fact on 09/04/2025.
Andrew P. Hider, President and CEO and Director of Baxter International Inc. (BAX), reported issuance of equity awards on 09/02/2025. He received 236,237 restricted stock units (RSUs) as a make-whole award for unvested prior employer equity and 131,813 RSUs as a pro rata 2025 annual grant, bringing his total reported common stock beneficial ownership to 368,050 shares after the transactions. He also received stock options covering 465,651 shares with a $24.17 exercise price, exercisable in three equal annual installments beginning 09/02/2026 and expiring 09/02/2035. The RSUs vest in three equal annual installments starting 09/02/2026, with accelerated vesting on certain termination events. The Form 4 was signed by an attorney-in-fact on 09/04/2025.
Joel T. Grade, EVP and CFO of Baxter International Inc. (BAX), reported a grant of 102,712 restricted stock units (RSUs) on 09/02/2025 that will vest on 09/05/2028, subject to the Amended and Restated Baxter International Inc. 2021 Incentive Plan vesting conditions. The RSUs will vest immediately if the reporting person’s employment is terminated without Cause as defined in the plan. After the reported transaction, the filing shows 222,560 shares beneficially owned, which includes automatic dividend reinvestment and shares held in Baxter’s Employee Stock Plan. The Form 4 was signed by an attorney-in-fact on 09/04/2025.
Baxter International (BAX) insider James W. Borzi, EVP and Chief Supply Chain Officer, reported a disposition of 1,848 shares on 09/02/2025 at $24.17 per share. The filing explains these shares were forfeited to cover tax withholding related to vested restricted stock units that settled on 09/02/2025 from an award granted 09/01/2023. After the transaction, Borzi beneficially owns 71,948 shares, which includes automatic dividend reinvestment. The Form 4 was signed by an attorney-in-fact on behalf of Borzi on 09/04/2025.